Bear markets are the best friend of an income-oriented, long-term investor. This is because investors are able to stretch their dividend income further with new purchases than would otherwise be the case.
With the S&P 500 index getting hammered 22% so far in 2022, there are tons of stocks that have been unfairly cut in half or more this year. And the nutrition and weight loss stock Medifast (NYSE: MED) , down 53% year to date, is arguably one of those stocks that has been unjustly punished.
Let's take a look at why the stock's monstrous 6.4% dividend yield and obscenely cheap valuation could prove to be a great buy for the long run.
For further details see:
Buy This Undervalued Stock Before Everyone Else Does